Close
Close

Incyte Corporation - Graft-versus-host Disease (GVHD)

Partner

Not provided

Rare Disease

Graft-versus-host Disease (GVHD)

Sponsor

Incyte Corporation

Access Program Information

To provide ruxolitinib through an expanded access program for the treatment of graft-versus-host disease (GVHD) in United States to patients who are ineligible or unable to participate in any actively enrolling Incyte-sponsored clinical studies for ruxolitinib in the treatment of GVHD.

Contact

Contact: Incyte Corporation Call Center (US) (1.855.463.3463)

Locations

Free Newsletter